Biotech RadarJobs updated

COMPANY

Janux Therapeutics

HQ: San Diego, CA source · januxrx.com ↗ · West Coast

Clinical Phase 1

14 open jobs · last seen Oct 23, 2026 · 8 sources

Keywords: oncology immunology Prostate Cancer Metastatic Castration-resistant Prostate Cancer Castration-Resistant Prostate Cancer Metastatic Prostate Cancer Castration Resistant Prostatic Cancer Non-Small Cell Lung Cancer Renal Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Colorectal Carcinoma Small Cell Lung Cancer Pancreatic Ductal Adenocarcinoma Triple-negative Breast Cancer Autoimmune JANX007 JANX013 JANX014 JANX008 JANX011

Profile checked Oct 10, 2026

Since the raise (Dec 4, 2024): 14 of 14 open jobs were first seen after it.

14Open jobs$350.0MRaised (2 yrs)5Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior/Executive Director, Translational Systems ImmunologySan Diego, CAOct 14, 2026Oct 14, 2026
Vice President, Investor Relations & Corporate CommunicationsSan Diego, CAOct 9, 2026Oct 9, 2026
Manager, Clinical Supply Chain (Ancillary Supplies)San Diego, CAOct 8, 2026Oct 11, 2026
HR & Talent CoordinatorSan Diego, CAOct 8, 2026Oct 9, 2026
Principal Scientist, Analytical Development & FormulationSan Diego, CASep 25, 2026Oct 9, 2026

See all 14 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Board tracked Radar started tracking this company’s job board (14 open jobs at last check). source ↗
  2. Trial start 1: Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC source ↗
  3. Trial start Phase 1: Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer source ↗
  4. Trial start Early phase 1: Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability. source ↗
  5. Partnership Partnership / licensing: $800M (upfront, as published); deal value up to $50M (kept separate from upfront), announced Jan 22, 2026. Source: SEC filing. source ↗
  6. Raise Follow-on offering: $350M (total, as published), announced Dec 4, 2024. Source: SEC filing. source ↗
  7. Trial start Phase 1: Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies source ↗
  8. Trial start Phase 1: Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 14

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior/Executive Director, Translational Systems ImmunologySan Diego, CAOct 14, 2026Oct 14, 2026Executive
Vice President, Investor Relations & Corporate CommunicationsSan Diego, CAOct 9, 2026Oct 9, 2026Executive
Manager, Clinical Supply Chain (Ancillary Supplies)San Diego, CAOct 8, 2026Oct 11, 2026Mid
HR & Talent CoordinatorSan Diego, CAOct 8, 2026Oct 9, 2026Entry
Principal Scientist, Analytical Development & FormulationSan Diego, CASep 25, 2026Oct 9, 2026Senior
Clinical Trial AssociateSan Diego, CASep 23, 2026Oct 9, 2026Entry
Research Associate, PharmacologySan Diego, CASep 16, 2026Oct 9, 2026Entry
Senior Research Associate, Analytical DevelopmentSan Diego, CASep 11, 2026Oct 9, 2026Senior
Senior Manager, Clinical ContractsSan Diego, CAAug 14, 2026Oct 9, 2026Senior
Clinical Trial Manager/Senior Clinical Trial Manager (AID)San Diego, CAAug 11, 2026Oct 9, 2026Mid
Sr. Clinical Trial ManagerSan Diego, CAJul 28, 2026Oct 9, 2026Senior
Vice President, Clinical Operations (AID)San Diego, CAMay 5, 2026Oct 9, 2026Executive
Senior Director, Global Regulatory AffairsSan Diego, CAFeb 6, 2026Oct 9, 2026Senior
Vice President / Senior Vice President, Clinical Development (AID)San Diego, CADec 12, 2025Oct 9, 2026Executive

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $350.0M. Last 2 years.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT07813637Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC1RecruitingSep 10, 20262029-07 (estimated)
NCT07545811Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate CancerPhase 1RecruitingApr 15, 20262028-05 (estimated)
NCT05519449Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)Phase 1RecruitingSep 15, 20222027-07 (estimated)
NCT05783622Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesPhase 1Active, not recruitingApr 19, 2023Jul 31, 2026 (estimated)
NCT07291323Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.Early phase 1RecruitingFeb 16, 20262026-10 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Janux Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback